Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality

• Published in: Journal of biomolecular structure & dynamics 2022-01, Vol.40 (20), p.10454-10469
• Main Authors: Rizwan, Tayyeba, Kothidar, Akansha, Meghwani, Himanshu, Sharma, Vaibhav, Shobhawat, Rahul, Saini, Rajpal, Vaishnav, Hemendra Kumar, Singh, Vikramaditya, Pratap, Mukut, Sihag, Hitaishi, Kumar, Shakti, Dey, Joy Kumar, Dey, Sanjay Kumar
• Format: Article
• Language: English
• Subjects: COVID-19; COVID-19 - mortality; COVID-19 - virology; envelope protein; Humans; ion-channel; Mutation; mutations correlated with mortalities; SARS-CoV-2; SARS-CoV-2 - genetics; viroporin; Viroporin Proteins - genetics
• ISSN: 0739-1102; 1538-0254; 1538-0254
• DOI: 10.1080/07391102.2021.1944319

One major obstacle in designing a successful therapeutic regimen to combat COVID-19 pandemic is the frequent occurrence of mutations in the SARS-CoV-2 resulting in patient to patient variations. Out of the four structural proteins of SARS-CoV-2 namely, spike, envelope, nucleocapsid and membrane, envelope protein governs the virus pathogenicity and induction of acute-respiratory-distress-syndrome which is the major cause of death in COVID-19 patients. These effects are facilitated by the viroporin (ion-channel) like activities of the envelope protein. Our current work reports metagenomic analysis of envelope protein at the amino acid sequence level through mining all the available SARS-CoV-2 genomes from the GISAID and coronapp servers. We found majority of mutations in envelope protein were localized at or near PDZ binding motif. Our analysis also demonstrates that the acquired mutations might have important implications on its structure and ion-channel activity. A statistical correlation between specific mutations (e.g. F4F, R69I, P71L, L73F) with patient mortalities were also observed, based on the patient data available for 18,691 SARS-CoV-2-genomes in the GISAID database till 30 April 2021. Albeit, whether these mutations exist as the cause or the effect of co-infections and/or co-morbid disorders within COVID-19 patients is still unclear. Moreover, most of the current vaccine and therapeutic interventions are revolving around spike protein. However, emphasizing on envelope protein's (1) conserved epitopes, (2) pathogenicity attenuating mutations, and (3) mutations present in the deceased patients, as reported in our present study, new directions to the ongoing efforts of therapeutic developments against COVID-19 can be achieved by targeting envelope viroporin. Communicated by Ramaswamy H. Sarma